Jiangsu Aidea Pharmaceutical's (SHA:688488) core anti-HIV drug is officially authorized for commercial sale in Zanzibar, an East African region that is part of Zanzibar, according to a Shanghai bourse filing on Monday.
The Chinese pharmaceutical company received a drug registration certificate for the ainuomiti tablets from the Zanzibar Food and Drug Agency.
Aidea said the approval market the first use of the drug in a non-Asian country. Africa is the region with the highest proportion of HIV patients in the world, the filing said.
The company's shares jumped over 7% during afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments